Selected article for: "better understand and virus spread"

Author: Ky, Bonnie; Mann, Douglas L.
Title: COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
  • Cord-id: y74jbnb2
  • Document date: 2020_4_16
  • ID: y74jbnb2
    Snippet: Abstract The COVID-19 pandemic has resulted in a proliferation of clinical trials that are designed to slow the spread of SARS-CoV-2, the virus that causes COVID-19. The overwhelming majority of cardiovascular and cancer patients are at increased risk for SARS-CoV-2 infection; accordingly, the cardiovascular and cardio-oncology communities are playing a major role in caring for COVID-19 patients. Many of the therapeutic agents that are being used to treat patients with COVID-19 are repurposed tr
    Document: Abstract The COVID-19 pandemic has resulted in a proliferation of clinical trials that are designed to slow the spread of SARS-CoV-2, the virus that causes COVID-19. The overwhelming majority of cardiovascular and cancer patients are at increased risk for SARS-CoV-2 infection; accordingly, the cardiovascular and cardio-oncology communities are playing a major role in caring for COVID-19 patients. Many of the therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, drugs that were not effective in Ebola patients, or treatments for malaria that were developed decades ago, and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here we have provided a foundation for cardiovascular and cardio-oncology physicians who are on the frontline providing care to COVID-19 patients, so that they can better understand the emerging cardiovascular epidemiology of COVID-19, as well as the biological rationale for the clinical trials that are ongoing for the treatment of COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • ace angiotensin ii and active form: 1, 2
    • ace angiotensin ii and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • ace angiotensin ii and lung injury model: 1
    • ace angiotensin ii at1 axis and lung injury: 1
    • ace angiotensin ii axis at1 and lung injury: 1
    • ace inhibitor and action mechanism: 1, 2, 3, 4
    • ace inhibitor and lung injury: 1, 2, 3, 4